Talon Pharmaceuticals was founded in 2012 and is focused on the discovery and development  of small molecule drugs for neurodegenerative disorders. Talon is building a portfolio of single drugs and combinations that target more than one mechanism of action (multi-action drugs). We are delivering the next generation of small molecule therapeutics for improving the quality of life of patients living with Parkinson’s disease.  We utilize translational and knowledge/structure-based approaches to advance purpose-built medicines for the treatment of symptoms and disease progression.